EMA/201814/2023

European Medicines Agency decision
P/0190/2023

of 15 May 2023


Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.
European Medicines Agency decision
P/0190/2023

of 15 May 2023


The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency’s decision P/0461/2020 issued on 4 December 2020 and the decision P/0399/2022 issued on 9 September 2022,

Having regard to the application submitted by Janssen-Cilag International NV on 19 December 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 31 March 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

---

Has adopted this decision:

**Article 1**

Changes to the agreed paediatric investigation plan for guselkumab (Tremfya), solution for injection in pre-filled pen, solution for injection in pre-filled syringe, solution for injection, subcutaneous use, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

**Article 2**

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/0073/2016 issued on 18 March 2016, including subsequent modifications thereof.

**Article 3**

This decision is addressed to Janssen-Cilag International NV, Turnhoutseweg 30, 2340 – Beerse, Belgium.
Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan
EMEA-001523-PIP04-19-M02

Scope of the application

Active substance(s):
Guselkumab

Invented name and authorisation status:
See Annex II

Condition(s):
Treatment of ulcerative colitis

Pharmaceutical form(s):
Solution for injection in pre-filled pen
Solution for injection in pre-filled syringe
Solution for injection

Route(s) of administration:
Subcutaneous use
Intravenous use

Name/corporate name of the PIP applicant:
Janssen-Cilag International NV

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Janssen-Cilag International NV submitted to the European Medicines Agency on 19 December 2022 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency’s decision P/0461/2020 issued on 4 December 2020 and the decision P/0399/2022 issued on 9 September 2022.

The application for modification proposed changes to the agreed paediatric investigation plan.
The procedure started on 31 January 2023.

**Scope of the modification**

Some measures of the Paediatric Investigation Plan have been modified.

**Opinion**

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)
1. Waiver

1.1. Condition:

Treatment of ulcerative colitis

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- solution for injection in pre-filled pen, solution for injection in pre-filled syringe, solution for injection, subcutaneous use, intravenous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of ulcerative colitis

2.1.1. Indication(s) targeted by the PIP

Treatment of moderately to severely active ulcerative colitis in paediatric subjects from 2 to less than 18 years of age, who have had an inadequate response, lost response, or were intolerant to either conventional therapy or biologic therapy.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection in pre-filled pen
Solution for injection in pre-filled syringe
Solution for injection

2.1.4. Measures

<table>
<thead>
<tr>
<th>Area</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality-related studies</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Non-clinical studies</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Clinical studies</td>
<td>Study 1 (CNTO1959PUC3001)</td>
</tr>
<tr>
<td></td>
<td>Open-label induction study in which patients receive either intravenous (IV) or subcutaneous (SC) guselkumab induction dosing, followed by a randomized, double-blind, 2-arm study of subcutaneous (SC) guselkumab maintenance dosing (two different dose levels) to assess pharmacokinetics</td>
</tr>
</tbody>
</table>
(PK), efficacy, and safety in paediatric subjects from 2 to less than 18 years of age with moderately to severely active ulcerative colitis, who have had an inadequate response, lost response, or were intolerant to either conventional therapy or biologic therapy.

Extrapolation, modelling and simulation studies

<table>
<thead>
<tr>
<th>Study 2</th>
<th>Extrapolation/interpolation population PK model.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 3</td>
<td>Extrapolation/interpolation exposure response model.</td>
</tr>
</tbody>
</table>

Other studies

Not applicable

Other measures

Not applicable

3. Follow-up, completion and deferral of PIP

| Concerns on potential long term safety/efficacy issues in relation to paediatric use: | No |
| Date of completion of the paediatric investigation plan: | By November 2027 |
| Deferral for one or more measures contained in the paediatric investigation plan: | Yes |
Annex II

Information about the authorised medicinal product
Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of plaque psoriasis

Authorised indication(s):

- Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
  - Invented name(s): Tremfya
  - Authorised pharmaceutical form(s): Solution for injection in pre-filled syringe; Solution for injection in pre-filled pen
  - Authorised route(s) of administration: Subcutaneous use
  - Authorised via centralised procedure

2. Treatment of psoriatic arthritis

Authorised indication(s):

- Tremfya, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.
  - Invented name(s): Tremfya
  - Authorised pharmaceutical form(s): Solution for injection in pre-filled syringe; Solution for injection in pre-filled pen
  - Authorised route(s) of administration: Subcutaneous use
  - Authorised via centralised procedure